Everest Medicines Ltd. (HK:1952) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Everest Medicines has announced the approval of its kidney disease drug NEFECON by the Taiwan Food and Drug Administration, marking a significant expansion in its treatment reach for IgA nephropathy, particularly in Asia where the condition is more prevalent. The company also highlighted promising results from a two-year clinical trial in China, showing substantial kidney function protection and reduction in proteinuria among patients. With approvals across several Asian regions, NEFECON is poised to become a leading treatment option for IgAN patients.
For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.